A Phase II, Randomized, Controlled, Observer-Blind, Clinical Study to Evaluate the Humoral and Cell Mediated Immunity and Safety of Two Intramuscular Doses of Fluad® or Agrippal® in Previously Unvaccinated Healthy Subjects Aged 6 to <36 Months To explore the cell mediated immune (CMI) responses to two 0.25 mL IM injections of Fluad or to two 0.25 mL IM injections of Agrippal as determined by the quality and quantity of the antigen-specific ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study to Evaluate the Safety and Immunogenicity of Travel Vaccines when Administered Concomitantly with Meningococcal ACWY Conjugate Vaccine in Healthy Adults Primary Africa/Latam Traveler Scheme  To establish the non-inferiority of typhoid Vi polysaccharide and yellow fever vaccines given concomitantly with MenACWY-CRM to typhoid Vi polysaccharide and...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase IV, Single-Centre, Observer-Blind, Controlled, Randomized Study to Compare the Safety and Immunogenicity of Fluvirin® to Influvac® Administered to Healthy Children 3 to 12 Years of Age To evaluate the immunogenicity of one 0.5mL and two 0.5mL intramuscular (IM) injections of FLUVIRIN® and Agrippal® administered 4 weeks apart

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase IIIb, Open-Label, Controlled, Multi-Center Study to Evaluate the Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine Primary: To assess the safety and tolerability of a dose of MenACWY in subjects who were previously vaccinated with one or two doses of MenACWY or MenC. Co-primary: 1.To evaluate the persistence of th...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Trial conducted in more then one site to assess safety of the Novartis vaccine against meningititis B injected at 0 and after 2 months in adults at risk because managing meningoccocus type B or travelling in geographic area where Meningitis B is highly present Studio condotto in piu' centri per valutare la sicurezza del vaccino Novartis contro la meningite B quando somministrato a 0 e dopo due mesi in adulti a rischio poiche' sono a contatto con meningococco di tipo B o viaggiano in aree geografiche dove la meningite B e' altamente presente To descriptively assess the safety of Novartis rMenB+OMV NZ in healthy at-risk adults when administered at a 0, 2- month schedule, throughout the clinical study. valutare la sicurezza del vacci...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Randomized, Single-blind, Dose-Ranging, Study to Evaluate Immunogenicity, Safety and Tolerability of Different Formulations of Adjuvanted and non Adjuvanted Egg-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Subjects 18 or More Years of Age To identify the preferred vaccine formulation (with and without MF59), dosage (of antigen and adjuvant) and schedule (one or two administrations) of the egg-derived H1N1sw monovalent vaccine in health...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase 3, Open label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster at 12 Months of Age or as a Two-dose Catch-up to Healthy Toddlers Who Participated in Study V72P13 Demonstration of a sufficient immune response following a fourth (booster) dose of rMenB+OMV NZ administered at 12 months of age, either with or without concomitant MMRV vaccination, to toddlers previ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase 2b, Open Label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis Meningococcal B Recombinant Vaccine Administered at 12, 18 or 24 Months of Age in Subjects Who Previously Received a Three-Dose Primary Series of the Novartis Meningococcal B Recombinant Vaccine as Infants in Study V72P12 To demonstrate a sufficient immune response following a fourth (booster) dose of rMenB+OMV NZ in at least one of the time points, when given at 12, 18 or 24 months of age to toddlers previously primed...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase III, Randomized, Observer-Blind, Placebo-Controlled, Multicenter Study to Assess Clinical Efficacy of a Cell-Derived Subunit Influenza Vaccine and an Egg-Derived Subunit Influenza Vaccine in the 2007-2008 Influenza Season in Healthy Adult Subjects •To demonstrate protection of a cell-derived influenza vaccine compared to placebo against illness caused by virus-confirmed community-acquired influenza wild type strains antigenically similar to th...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase 2, Single Blind, Single Center, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine +/- OMV, when Administered to Healthy Infants 6-8 months old To explore the immunogenicity of Novartis rMenB Vaccine +/- OMV when administered to healthy infants, at 30 days after the second and the third dose, by evaluation of the breadth of bactericidal activ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune